readthroughSign in
Nov 12, 2026Quarterly update

Sutro Biopharma reports Q3 2026 results, advances ADC pipeline and Astellas collaboration

Sutro says STRO-004 and STRO-006 are both in the clinic, STRO-227 is headed there in early 2027, and cash runs into first half of 2028.

Sutro Biopharma reported third quarter 2026 results on November 12, 2026, highlighting progress across its antibody drug conjugate pipeline. STRO-004, a Tissue Factor-targeting DAR8 exatecan ADC, is being evaluated in the Phase 1 STRIVE-01 study in patients with advanced solid tumors; initial dose escalation in 49 heavily pretreated patients reported in August 2026 showed confirmed and ongoing unconfirmed partial responses across three tumor types, along with favorable tolerability and a differentiated pharmacokinetic profile. Dose optimization continues in backfill cohorts, and the company plans its next study update along with initiation of expansion cohorts in the first half of 2027.1

STRO-006, an ITGB6-targeting ADC with a DAR8 exatecan payload, began Phase 1 dosing in October 2026 in a study evaluating safety, tolerability, pharmacokinetics and preliminary antitumor activity in adults with advanced or metastatic solid tumors, with an initial data update anticipated in the second half of 2027.1

STRO-227, a dual-payload ADC targeting PTK7 combining MMAE and exatecan payloads, is advancing toward a Phase 1 trial start in early 2027.1

Under the Astellas collaboration on dual-payload immunostimulatory ADCs, the first program targeting TROP2 continues dosing patients, and a second program targeting B7-H3 began dosing patients, triggering a $10 million milestone payment received by Sutro in October 2026.1

On the balance sheet, Sutro had $142.2 million in cash, cash equivalents and marketable securities as of September 30, 2026, down from $164.3 million as of June 30, 2026, with the company saying this is expected to support operations into the first half of 2028.1 Revenue was $9.1 million for the quarter, compared with $9.7 million in the same quarter of 2025, related principally to the Astellas collaboration.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.